

Belimumab (BENLYSTA)

Infusion Therapy Plan Orders

Page 1 of 2

Name:

Group Health Member I.D. #_____

Date of Birth

Instructions to Provider

Review orders and note any changes. All orders with 🗹 will be placed unless otherwise noted. Please fax completed order form to the infusion center where the patient will be receiving treatment (see fax numbers page 2). Lab orders are not included on this form – place orders via usual method. Lab monitoring is the responsibility of the ordering physician.

Please complete all of the following:

Pre-Service Authorization has been obtained by Group Health Fax: 1-888-282-2685 Voice: 1-800-289-1363				
	Diagnosis: ICD-10 code (REQUIRED):			
Weight:kg	ICD-10 description			
General Plan Communicatio	מר			
 Induction Schedule: Infuse belimumab at 0, 2, 4, then every 4 weeks. 				
-				
	9S:			
Provider Information				
 Use with caution in patients with chronic infections. 				
	t be given 30 days before or concurrently during treatment.			
Belimumab is not recommended to be used in combination with other biologics or IV cyclophosphamide.				
Infusion Therapy				
 Belimumab (BENLYSTA) in 0.9% sodium chloride 250 mL IV infusion Dose: □ 10 mg/kg = mg (consider rounding to nearest combination of vial sizes: 400mg & 120 mg) Route: Intravenous Frequency: Every 2 weeks x 3 doses, then every 4 weeks thereafter. Infusion Duration: 60 minutes If infusion-related reaction: STOP infusion immediately; 2) Increase primary infusion to wide open rate; 3) Administer PRN medications per hypersensitivity protocol; 4) Notify MD Note any changes to above regimen:				
Pre-Meds				
Dose: 650 mg Route Frequency: Once PRN, infusions cetirizine (ZYRTEC) tak Dose: 10 mg Rou	 Dose: 650 mg Route: Oral Frequency: Once PRN, 30 minutes prior to belimumab infusion IF patient had reaction to previous belimumab infusions. cetirizine (ZYRTEC) tablet Dose: 10 mg Route: Oral Frequency: Once PRN, at least 60 minutes prior to belimumab infusion IF patient had reaction to previous 			
Other: Dose: Rou	oute: Oral Frequency: Once, 30 minutes prior to belimumab infusion			
No routine pre-medicat medications for future c	ions necessary. Above pre-meds may be given if patient has reaction and requires pre- doses.			
Provider Signature: Date:				
Printed Name:	Phone: Fax:			

HIM Revision Date: 9/30/2015 Group Health Cooperative <Reference#115127>



Belimumab (BENLYSTA) Infusion Therapy Plan Orders

Page 2 of 2

Name:

Group Health Member I.D. #_____

Date of Birth _

N/ Line	A ava				
IV Line					
	0.9% sodium chloride infusion 250 mL				
	Rate: 30 mL/hr Route: Intravenous Frequency: Run continuously to keep vein open				
	Start peripheral IV if no central line				
\square	heparin flush 100 unit/mL				
	Dose: 500 units Route: Intracatheter Frequency: PRN for IV line care per Nursing Policy				
Infusio	n Reaction Meds				
\checkmark	albuterol (PROVENTIL) neubulizer solution 0.083%				
	Dose: 2.5 mg Route: Nebulization Frequency: PRN for shortness of breath/wheezing				
\checkmark					
	Dose: 25 mg Route: Intravenous				
	<i>Frequency:</i> Once PRN, May repeat x1 for urticaria, pruritis, shortness of breath. May repeat in 15 minutes if				
	symptoms not resolved.				
▼	EPINEPHrine 1 mg/mL (1:1000) injectable				
Dose: 0.3 mg Route: Intramuscular					
	Frequency: Once PRN for anaphylaxis. Notify physician if administered.				
	hydrocortisone sodium succinate (SOLU-CORTEF) injectable				
	Dose: 100 mg Route: Intravenous Frequency: Once PRN for hypersensitivity				
Lab Re	view for Nursing				
•	Ensure baseline labs anti-nuclear antibody (ANA) and/or anti-double-stranded DNA (anti-dsDNA) have been				
	drawn prior to initial treatment if provider has ordered.				
Nursin	g Orders				
	Weight should be recorded at least every 6 months or more frequently as appropriate. Notify physician if				
	weight has changed 10% or greater from baseline.				
	Do not administer belimumab and notify provider if patient has a temperature greater than 100 degrees F,				
	complains of symptoms of acute viral or bacterial illness, or if patient is taking antibiotics for current infection.				
 Flush belimumab tubing with ONLY with 0.9% sodium chloride (never D5W). Do not infuse any other agents 					
•					
	in the same line.				
 Monitor patient every 30 minutes during infusion and for 30 minutes after infusion for evidence of adverse 					
reaction.					
 Discontinue IV line 30 minutes after therapy complete and patient stabilized. 					
Refere	nces				
•	Benlysta prescribing information.				
•					
Group Health Infusion Locations					
Bellevue	Medical Center Silverdale Medical Center				
	NE 10 th St, Bellevue, WA 98004 10452 Silverdale Way NW, Silverdale, WA 98383				
Fax: 425-502-3512 Phone: 425-502-3510 Fax: 360-307-7493 Phone: 360-307-7444					
Capitol Hill Medical Center Tacoma Medical Center					
201 16 th Ave E, Seattle WA 98112 209 Martin Luther King Jr Way, Tacoma, WA 98405					
Fax: 206-326-2104 Phone: 206-326-3109 Fax: 253-383-6262 Phone: 253-596-3666					
Everett Medical Center Olympia Medical Center					
2930 Maple St, Everett, WA 98201 700 Lily Road N.E., Olympia, WA 98506					
Fax: 425-261-1659 Phone: 425-261-1681 Fax: 360-923-7106 Phone: 360-923-7164					
Riverfront Medical Center – Spokane					
W 322 North River Drive, Spokane, WA 99201 Fax: 509-324-7168 Phone: 509-241-2073					
Fax: 5	509-324-7168 Phone: 509-241-2073				

Provider Signature:		Date:	
Printed Name:	Phone:	Fax:	
	HIM Revision Date: 9/30	/2015 Group Health Cooperative <reference#115127></reference#115127>	